Skip Navigation
Genetics Home Reference: your guide to understanding genetic conditions
http://ghr.nlm.nih.gov/     A service of the U.S. National Library of Medicine®

MAPT

Reviewed March 2011

What is the official name of the MAPT gene?

The official name of this gene is “microtubule-associated protein tau.”

MAPT is the gene's official symbol. The MAPT gene is also known by other names, listed below.

What is the normal function of the MAPT gene?

The MAPT gene provides instructions for making a protein called tau. This protein is found throughout the nervous system, including in nerve cells (neurons) in the brain. It is involved in assembling and stabilizing microtubules, which are rigid, hollow fibers that make up the cell's structural framework (the cytoskeleton). Microtubules help cells maintain their shape, assist in the process of cell division, and are essential for the transport of materials within cells.

Six different versions (isoforms) of the tau protein are produced in the adult brain. The isoforms vary in length from 352 to 441 protein building blocks (amino acids). A region of the protein called the microtubule-binding domain, which is the part of the protein that attaches (binds) to microtubules, also varies among the isoforms. In three of the isoforms, the microtubule-binding domain contains three repeated segments. In the other three isoforms, this domain contains four repeated segments. Typically, the brain has approximately the same amount of three-repeat isoforms and four-repeat isoforms. This balance appears to be essential for the normal function of neurons.

How are changes in the MAPT gene related to health conditions?

frontotemporal dementia with parkinsonism-17 - caused by mutations in the MAPT gene

More than 40 mutations in the MAPT gene have been found to cause frontotemporal dementia with parkinsonism-17 (FTDP-17). Some of these mutations change single amino acids in the tau protein, most often in the microtubule-binding region. These mutations reduce tau's ability to bind to microtubules, which disrupts many important cell functions.

Other MAPT gene mutations change the way the gene's instructions are used to build the tau protein. Most of these mutations increase the production of tau with four repeated segments compared to the production of tau with three repeated segments. The resulting imbalance of tau isoforms in the brain interferes with the normal functions of brain cells.

In ways that are not fully understood, the MAPT gene mutations responsible for FTDP-17 lead to an accumulation of abnormal tau in neurons and other brain cells. These clumps of defective tau build up over time, although it is unclear what effect they have on cell function and survival. FTDP-17 is characterized by the gradual death of cells in areas of the brain called the frontal and temporal lobes. The frontal lobes are involved in reasoning, planning, judgment, and problem-solving, while the temporal lobes help process hearing, speech, memory, and emotion. The loss of cells in these brain regions leads to the major features of FTDP-17, including changes in personality and behavior, speech and language abnormalities, and problems with movement.

progressive supranuclear palsy - caused by mutations in the MAPT gene

Several mutations in the MAPT gene have been found to cause progressive supranuclear palsy. However, mutations in this gene appear to be a rare cause of this disorder.

At least one normal variation (polymorphism) in the MAPT gene has been associated with an increased risk of developing progressive supranuclear palsy. This polymorphism, known as the H1 haplotype, is found much more frequently in people with progressive supranuclear palsy than in the general population. It is unclear exactly how this genetic variation increases the risk of developing this disease.

The features of progressive supranuclear palsy appear to be related to abnormalities in the tau protein. In people with MAPT gene mutations, genetic changes disrupt the protein's normal structure and function. However, abnormal tau is also found in people without MAPT gene mutations. The defective tau protein assembles into abnormal clumps within neurons and other brain cells, although it is unclear what effect these clumps have on cell function and survival. Progressive supranuclear palsy is characterized by the gradual death of brain cells, particularly in structures deep within the brain that are essential for coordinating movement. This loss of brain cells underlies the major features of progressive supranuclear palsy, including problems with movement, vision, speech, and thinking (cognition).

other disorders - caused by mutations in the MAPT gene

Mutations in the MAPT gene have also been found to cause other brain disorders similar to FTDP-17 and progressive supranuclear palsy. These disorders include corticobasal degeneration, tauopathy with respiratory failure, and a form of dementia with seizures (epilepsy). Although these conditions have somewhat different patterns of signs and symptoms, they all involve changes in personality, behavior, or cognition and problems with movement. The MAPT gene mutations responsible for these disorders lead to a buildup of abnormal tau in brain cells. Although the effect of tau accumulation on cell function and survival is unknown, these disorders are characterized by the death of brain cells in regions of the brain essential for cognition, emotion, and coordinating movement.

Because all of these diseases are characterized by an abnormal buildup of tau in the brain, they are known as tauopathies. Some researchers suggest that, instead of being described as separate disorders, the group of tauopathies caused by mutations in the MAPT gene should be considered as part of a spectrum with varying signs and symptoms.

Where is the MAPT gene located?

Cytogenetic Location: 17q21.1

Molecular Location on chromosome 17: base pairs 45,894,335 to 46,028,333

The MAPT gene is located on the long (q) arm of chromosome 17 at position 21.1.

The MAPT gene is located on the long (q) arm of chromosome 17 at position 21.1.

More precisely, the MAPT gene is located from base pair 45,894,335 to base pair 46,028,333 on chromosome 17.

See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.

Where can I find additional information about MAPT?

You and your healthcare professional may find the following resources about MAPT helpful.

You may also be interested in these resources, which are designed for genetics professionals and researchers.

What other names do people use for the MAPT gene or gene products?

  • DDPAC
  • FLJ31424
  • FTDP-17
  • G protein beta1/gamma2 subunit-interacting factor 1
  • MAPTL
  • MGC138549
  • MSTD
  • MTBT1
  • MTBT2
  • neurofibrillary tangle protein
  • paired helical filament-tau
  • PHF-tau
  • PPND
  • PPP1R103
  • TAU
  • TAU_HUMAN

See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.

What glossary definitions help with understanding MAPT?

acids ; cell ; cell division ; cognition ; cytoskeleton ; dementia ; domain ; epilepsy ; gene ; genetic variation ; haplotype ; isoforms ; microtubule ; nervous system ; palsy ; parkinsonism ; polymorphism ; population ; protein ; respiratory ; spectrum ; subunit

You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://ghr.nlm.nih.gov/glossary).

References

  • Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999 Apr;8(4):711-5. (http://www.ncbi.nlm.nih.gov/pubmed/10072441?dopt=Abstract)
  • Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997 Feb;41(2):277-81. (http://www.ncbi.nlm.nih.gov/pubmed/9029080?dopt=Abstract)
  • Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2004 Feb;15(1):45-9. Review. (http://www.ncbi.nlm.nih.gov/pubmed/15036206?dopt=Abstract)
  • Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998 Jun 18;393(6686):702-5. (http://www.ncbi.nlm.nih.gov/pubmed/9641683?dopt=Abstract)
  • Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-59. Review. (http://www.ncbi.nlm.nih.gov/pubmed/11520930?dopt=Abstract)
  • Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Höglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, Wszolek ZK; Reisensburg Working Group for Tauopathies With Parkinsonism. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009 Mar;16(3):297-309. doi: 10.1111/j.1468-1331.2008.02513.x. Review. (http://www.ncbi.nlm.nih.gov/pubmed/19364361?dopt=Abstract)
  • NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/4137)
  • Nicholl DJ, Greenstone MA, Clarke CE, Rizzu P, Crooks D, Crowe A, Trojanowski JQ, Lee VM, Heutink P. An English kindred with a novel recessive tauopathy and respiratory failure. Ann Neurol. 2003 Nov;54(5):682-6. (http://www.ncbi.nlm.nih.gov/pubmed/14595660?dopt=Abstract)
  • Pastor P, Ezquerra M, Tolosa E, Muñoz E, Martí MJ, Valldeoriola F, Molinuevo JL, Calopa M, Oliva R. Further extension of the H1 haplotype associated with progressive supranuclear palsy. Mov Disord. 2002 May;17(3):550-6. (http://www.ncbi.nlm.nih.gov/pubmed/12112206?dopt=Abstract)
  • Rademakers R, Melquist S, Cruts M, Theuns J, Del-Favero J, Poorkaj P, Baker M, Sleegers K, Crook R, De Pooter T, Bel Kacem S, Adamson J, Van den Bossche D, Van den Broeck M, Gass J, Corsmit E, De Rijk P, Thomas N, Engelborghs S, Heckman M, Litvan I, Crook J, De Deyn PP, Dickson D, Schellenberg GD, Van Broeckhoven C, Hutton ML. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005 Nov 1;14(21):3281-92. Epub 2005 Sep 29. (http://www.ncbi.nlm.nih.gov/pubmed/16195395?dopt=Abstract)
  • Spillantini MG, Van Swieten JC, Goedert M. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Neurogenetics. 2000 Mar;2(4):193-205. Review. (http://www.ncbi.nlm.nih.gov/pubmed/10983715?dopt=Abstract)
  • van Swieten J, Spillantini MG. Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol. 2007 Jan;17(1):63-73. Review. (http://www.ncbi.nlm.nih.gov/pubmed/17493040?dopt=Abstract)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

 
Reviewed: March 2011
Published: September 15, 2014